Copyright 1998 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.1998
We read with interest the article by Learoyd et al1 concerning genetic testing for multiple endocrine neoplasia, type 2 (MEN 2). We generally agree with the conclusion of this article, but hold a different opinion in regard to the following. The authors state that genetic screening for RET proto-oncogene mutations in MEN 2 is a powerful diagnostic tool and that RET mutation carriers older than 6 years of age should undergo thyroidectomy immediately.
Takami H. RET Proto-oncogene Mutation Analysis for Multiple Endocrine Neoplasia, Type 2. Arch Surg. 1998;133(6):679. doi:
Customize your JAMA Network experience by selecting one or more topics from the list below.